Bayer Aktiengesellschaft BAYRY · OTC
$12.49 +1.30% (+$0.16)
Summary
34 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- Revenue fell by 4.8% a year over the last 3 years.
- Repaying its net debt would take 3.7 years of operating profit.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 1.1% a year over 5 years. Over the last 3 years it fell by 4.8% a year. For the next fiscal year analysts expect revenue to grow by 6.3%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of 1.66B €.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 57.9 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Small, at risk- Yield
- 0.26%
- Raised in a row
- 1 year
You receive $0.03 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
Neutral- Buy 1
- Hold 2
- Sell 0
No analyst has published a price target.
33% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.